Experimental and In Silico Analysis of Cordycepin and its Derivatives as Endometrial Cancer Treatment.

The aim of this study was to investigate the inhibition effects of cordycepin and its derivatives on endometrial cancer cell growth. Cytotoxicity MTT assays, clonogenic assays, and flow cytometry were used to observe the effects on apoptosis and regulation of the cell cycle of Ishikawa cells under various concentrations of cordycepin, cisplatin, and combinations of the two. Validated in silico docking simulations were performed on 31 cordycepin derivatives against adenosine deaminase (ADA) to predict their binding affinities and hence their potential tendency to be metabolized by ADA. Cordycepin has a significant dose-dependent inhibitory effect on cell proliferation. The combination of cordycepin and cisplatin produced greater inhibition effects than did cordycepin alone. Apoptosis investigations confirmed the ability of cordycepin to induce the apoptosis of Ishikawa cells. The in silico results indicate that compound MRS5698 is least metabolized by ADA and has acceptable drug likeness and safety profiles. This is the first study to confirm the cytotoxic effects of cordycepin on endometrial cancer cells. This study also identified cordycepin derivatives with promising pharmacological and pharmacokinetic properties for further investigation in the development of new treatments for endometrial cancer.

[1]  S. A. El‐Hawash,et al.  New benzothiophene derivatives as dual COX-1/2 and 5-LOX inhibitors: synthesis, biological evaluation and docking study. , 2017, Future medicinal chemistry.

[2]  Antonella Ciancetta,et al.  Structural Probing and Molecular Modeling of the A3 Adenosine Receptor: A Focus on Agonist Binding , 2017, Molecules.

[3]  P. Fong,et al.  Synergistic antibacterial effects of herbal extracts and antibiotics on methicillin-resistant Staphylococcus aureus: A computational and experimental study , 2017, Experimental biology and medicine.

[4]  H. Stark,et al.  Ciproxifan, a histamine H3 receptor antagonist, reversibly inhibits monoamine oxidase A and B , 2017, Scientific Reports.

[5]  Xiandong Tao,et al.  The effects of cordycepin on the cell proliferation, migration and apoptosis in human lung cancer cell lines A549 and NCI‐H460 , 2016, The Journal of pharmacy and pharmacology.

[6]  P. Fishman,et al.  The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis , 2016, Clinical Rheumatology.

[7]  W. Park,et al.  Cordycepin increases radiosensitivity in cervical cancer cells by overriding or prolonging radiation-induced G2/M arrest. , 2016, European journal of pharmacology.

[8]  Joanna L. Sharman,et al.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands , 2015, Nucleic Acids Res..

[9]  P. Fong,et al.  In silico prediction of prostaglandin D2 synthase inhibitors from herbal constituents for the treatment of hair loss. , 2015, Journal of ethnopharmacology.

[10]  M. Sturlese,et al.  The Influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl Moiety on the Adenosine Receptors Affinity Profile of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidine Derivatives , 2015, PloS one.

[11]  Istvan J Enyedy,et al.  In silico prediction of hERG inhibition. , 2015, Future medicinal chemistry.

[12]  S. Hirono,et al.  Inhibition of adenosine deaminase (ADA)-mediated metabolism of cordycepin by natural substances , 2015, Pharmacology research & perspectives.

[13]  Yu-chian Chen.  Beware of docking! , 2015, Trends in pharmacological sciences.

[14]  Zijian Li,et al.  A novel drug discovery strategy inspired by traditional medicine philosophies , 2015 .

[15]  K. Jacobson,et al.  Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states. , 2015, Brain : a journal of neurology.

[16]  Kazuki Nakamura,et al.  Anticancer and antimetastatic effects of cordycepin, an active component of Cordyceps sinensis. , 2015, Journal of pharmacological sciences.

[17]  Duo Yin,et al.  No Association Between p21 Gene rs1059234 Polymorphisms and Risk of Endometrial Cancer Among Han Women in Northeast China , 2014, Cell Biochemistry and Biophysics.

[18]  M. Einstein,et al.  Obesity and Age at Diagnosis of Endometrial Cancer , 2014, Obstetrics and gynecology.

[19]  Zhihai Liu,et al.  Comparative Assessment of Scoring Functions on an Updated Benchmark: 2. Evaluation Methods and General Results , 2014, J. Chem. Inf. Model..

[20]  Silvia Paoletta,et al.  Structural Probing of Off-Target G Protein-Coupled Receptor Activities within a Series of Adenosine/Adenine Congeners , 2014, PloS one.

[21]  P. Fong,et al.  In Silico Prediction of Tyrosinase and Adenylyl Cyclase Inhibitors from Natural Compounds , 2014, Natural product communications.

[22]  Wei Zhang,et al.  Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer , 2014, BMB reports.

[23]  A. Sharma,et al.  Cordycepin: a bioactive metabolite with therapeutic potential. , 2013, Life sciences.

[24]  Alan Bensoussan,et al.  Traditional Chinese Medicine in Cancer Care: A Review of Controlled Clinical Studies Published in Chinese , 2013, PloS one.

[25]  K. Jacobson,et al.  Adenosine receptor subtype 3 (A3AR) agonists as novel analgesics in chronic neuropathic pain , 2013 .

[26]  Matteo Floris,et al.  Adenosiland: walking through adenosine receptors landscape. , 2012, European journal of medicinal chemistry.

[27]  Feixiong Cheng,et al.  In silico Prediction of Chemical Ames Mutagenicity , 2012, J. Chem. Inf. Model..

[28]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[29]  K. Jacobson,et al.  Pharmacological and therapeutic effects of A3 adenosine receptor agonists. , 2012, Drug discovery today.

[30]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[31]  V. Singh,et al.  Inflammation, microenvironment, and the immune system in cancer progression. , 2009, Current pharmaceutical design.

[32]  Thomas Stützle,et al.  Empirical Scoring Functions for Advanced Protein-Ligand Docking with PLANTS , 2009, J. Chem. Inf. Model..

[33]  G. Chiappetta,et al.  Cl-IB-MECA inhibits human thyroid cancer cell proliferation independently of A3 adenosine receptor activation , 2008, Cancer biology & therapy.

[34]  J. Haveman,et al.  Clonogenic assay of cells in vitro , 2006, Nature Protocols.

[35]  R. Gambari,et al.  Elevated Expression of A3 Adenosine Receptors in Human Colorectal Cancer Is Reflected in Peripheral Blood Cells , 2004, Clinical Cancer Research.

[36]  A. Saboury,et al.  A product inhibition study on adenosine deaminase by spectroscopy and calorimetry. , 2002, Journal of biochemistry and molecular biology.

[37]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[38]  K. Hornbuckle,et al.  Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999 , 2001 .

[39]  P. Fishman,et al.  Adenosine acts as a chemoprotective agent by stimulating G‐CSF production: A role for A1 and A3 adenosine receptors , 2000, Journal of cellular physiology.

[40]  P. Fishman,et al.  Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth. , 1998, Cancer research.

[41]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[42]  N. Frimodt-Møller,et al.  Dicloxacillin and flucloxacillin: Pharmacokinetics, protein binding and serum bactericidal titers in healthy subjects after oral administration , 1995, Infection.

[43]  R. Scheife,et al.  Protein Binding: What Does it Mean? , 1989, DICP : the annals of pharmacotherapy.